Siren L.L.C. Reduces Position in Gossamer Bio, Inc. $GOSS

Key Points

• Siren L.L.C. reduced its stake in Gossamer Bio, Inc. by 3.8% during the first quarter, owning approximately 5.21 million shares worth about $5.73 million afterward.
• Gossamer Bio has received mixed analyst ratings, with Wall Street Zen downgrading the stock from "hold" to "sell," while Wedbush and Goldman Sachs set price targets of $5.00 and $8.00, respectively.
• The company's recent earnings report showed a revenue of $11.49 million, surpassing expectations, and a reported EPS of ($0.17) which beat the consensus estimate.

Siren L.L.C. reduced its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 3.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,208,968 shares of the company's stock after selling 207,000 shares during the quarter. Siren L.L.C. owned approximately 2.29% of Gossamer Bio worth $5,730,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Graham Capital Management L.P. purchased a new position in Gossamer Bio during the fourth quarter valued at $32,000. Virtu Financial LLC purchased a new position in Gossamer Bio during the first quarter valued at $38,000. Fullcircle Wealth LLC purchased a new position in Gossamer Bio during the fourth quarter valued at $43,000. Invesco Ltd. purchased a new position in Gossamer Bio during the first quarter valued at $48,000. Finally, Velan Capital Investment Management LP purchased a new position in Gossamer Bio during the fourth quarter valued at $68,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wedbush lifted their target price on Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. Scotiabank initiated coverage on Gossamer Bio in a research note on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price target for the company. The Goldman Sachs Group increased their price target on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Finally, Wall Street Zen lowered Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Gossamer Bio presently has a consensus rating of "Buy" and an average target price of $8.50.

Gossamer Bio Price Performance

Shares of Gossamer Bio stock traded down $0.01 during trading hours on Wednesday, reaching $2.59. The company's stock had a trading volume of 1,940,052 shares, compared to its average volume of 2,046,001. The firm has a 50 day moving average price of $1.81 and a 200-day moving average price of $1.37. Gossamer Bio, Inc. has a one year low of $0.66 and a one year high of $2.71. The company has a debt-to-equity ratio of 6.70, a current ratio of 4.40 and a quick ratio of 4.40. The stock has a market cap of $587.78 million, a P/E ratio of -4.17 and a beta of 1.95.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million for the quarter, compared to the consensus estimate of $4.12 million. On average, analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.